Fewer radiation sessions may keep breast cancer at bay

NCT ID NCT06443359

Ongoing Disease control Sponsor: Corewell Health East Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a shorter, more intense radiation schedule (hypofractionation) for women with breast cancer who have had surgery. The goal is to see if this approach is safe and effective at preventing cancer from coming back while reducing side effects like arm swelling. Fifty-six women will receive radiation to the breast or chest wall and nearby lymph nodes over about three weeks, and they will be followed for three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hypofractionated radiation therapy
What this could lead to: If successful, this could offer a more convenient and equally safe radiation schedule for breast cancer patients, reducing treatment visits and long-term arm swelling.
What could go wrong: This is a small, early-phase study with only 56 participants, so results may not apply to all patients. There is still a risk of cancer recurrence or side effects like lymphedema.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm lymphedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085, United States
Corewell Health Dearborn Hospital

Dearborn, Michigan, 48124, United States
Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.